Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Human Cancer Biology

TIE-2 and VEGFR Kinase Activities Drive Immunosuppressive Function of TIE-2–Expressing Monocytes in Human Breast Tumors

Mark Ibberson, Sylvian Bron, Nicolas Guex, Eveline Faes-van't Hull, Assia Ifticene-Treboux, Luc Henry, Hans-Anton Lehr, Jean-François Delaloye, George Coukos, Ioannis Xenarios and Marie-Agnès Doucey
Mark Ibberson
1Vital-IT, Swiss Institute of Bioinformatics; 2Ludwig Cancer Research Center; 3Centre du Sein, CHUV, University of Lausanne, Lausanne, Switzerland; and 4Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvian Bron
1Vital-IT, Swiss Institute of Bioinformatics; 2Ludwig Cancer Research Center; 3Centre du Sein, CHUV, University of Lausanne, Lausanne, Switzerland; and 4Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Guex
1Vital-IT, Swiss Institute of Bioinformatics; 2Ludwig Cancer Research Center; 3Centre du Sein, CHUV, University of Lausanne, Lausanne, Switzerland; and 4Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eveline Faes-van't Hull
1Vital-IT, Swiss Institute of Bioinformatics; 2Ludwig Cancer Research Center; 3Centre du Sein, CHUV, University of Lausanne, Lausanne, Switzerland; and 4Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Assia Ifticene-Treboux
1Vital-IT, Swiss Institute of Bioinformatics; 2Ludwig Cancer Research Center; 3Centre du Sein, CHUV, University of Lausanne, Lausanne, Switzerland; and 4Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luc Henry
1Vital-IT, Swiss Institute of Bioinformatics; 2Ludwig Cancer Research Center; 3Centre du Sein, CHUV, University of Lausanne, Lausanne, Switzerland; and 4Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Anton Lehr
1Vital-IT, Swiss Institute of Bioinformatics; 2Ludwig Cancer Research Center; 3Centre du Sein, CHUV, University of Lausanne, Lausanne, Switzerland; and 4Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-François Delaloye
1Vital-IT, Swiss Institute of Bioinformatics; 2Ludwig Cancer Research Center; 3Centre du Sein, CHUV, University of Lausanne, Lausanne, Switzerland; and 4Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Coukos
1Vital-IT, Swiss Institute of Bioinformatics; 2Ludwig Cancer Research Center; 3Centre du Sein, CHUV, University of Lausanne, Lausanne, Switzerland; and 4Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ioannis Xenarios
1Vital-IT, Swiss Institute of Bioinformatics; 2Ludwig Cancer Research Center; 3Centre du Sein, CHUV, University of Lausanne, Lausanne, Switzerland; and 4Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Agnès Doucey
1Vital-IT, Swiss Institute of Bioinformatics; 2Ludwig Cancer Research Center; 3Centre du Sein, CHUV, University of Lausanne, Lausanne, Switzerland; and 4Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-12-3181 Published July 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Tumor-associated TIE-2–expressing monocytes (TEM) are highly proangiogenic cells critical for tumor vascularization. We previously showed that, in human breast cancer, TIE-2 and VEGFR pathways control proangiogenic activity of TEMs. Here, we examine the contribution of these pathways to immunosuppressive activity of TEMs.

Experimental Design: We investigated the changes in immunosuppressive activity of TEMs and gene expression in response to specific kinase inhibitors of TIE-2 and VEGFR. The ability of tumor TEMs to suppress tumor-specific T-cell response mediated by tumor dendritic cells (DC) was measured in vitro. Characterization of TEM and DC phenotype in addition to their interaction with T cells was done using confocal microscopic images analysis of breast carcinomas.

Results: TEMs from breast tumors are able to suppress tumor-specific immune responses. Importantly, proangiogenic and suppressive functions of TEMs are similarly driven by TIE-2 and VEGFR kinase activity. Furthermore, we show that tumor TEMs can function as antigen-presenting cells and elicit a weak proliferation of T cells. Blocking TIE-2 and VEGFR kinase activity induced TEMs to change their phenotype into cells with features of myeloid dendritic cells. We show that immunosuppressive activity of TEMs is associated with high CD86 surface expression and extensive engagement of T regulatory cells in breast tumors. TIE-2 and VEGFR kinase activity was also necessary to maintain high CD86 surface expression levels and to convert T cells into regulatory cells.

Conclusions: These results suggest that TEMs are plastic cells that can be reverted from suppressive, proangiogenic cells into cells that are able to mediate an antitumoral immune response. Clin Cancer Res; 19(13); 3439–49. ©2013 AACR.

Footnotes

  • Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

  • Received October 10, 2012.
  • Revision received April 16, 2013.
  • Accepted April 19, 2013.
  • ©2013 American Association for Cancer Research.
View Full Text
PreviousNext
Back to top
Clinical Cancer Research: 19 (13)
July 2013
Volume 19, Issue 13
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
TIE-2 and VEGFR Kinase Activities Drive Immunosuppressive Function of TIE-2–Expressing Monocytes in Human Breast Tumors
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
TIE-2 and VEGFR Kinase Activities Drive Immunosuppressive Function of TIE-2–Expressing Monocytes in Human Breast Tumors
Mark Ibberson, Sylvian Bron, Nicolas Guex, Eveline Faes-van't Hull, Assia Ifticene-Treboux, Luc Henry, Hans-Anton Lehr, Jean-François Delaloye, George Coukos, Ioannis Xenarios and Marie-Agnès Doucey
Clin Cancer Res July 1 2013 (19) (13) 3439-3449; DOI: 10.1158/1078-0432.CCR-12-3181

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
TIE-2 and VEGFR Kinase Activities Drive Immunosuppressive Function of TIE-2–Expressing Monocytes in Human Breast Tumors
Mark Ibberson, Sylvian Bron, Nicolas Guex, Eveline Faes-van't Hull, Assia Ifticene-Treboux, Luc Henry, Hans-Anton Lehr, Jean-François Delaloye, George Coukos, Ioannis Xenarios and Marie-Agnès Doucey
Clin Cancer Res July 1 2013 (19) (13) 3439-3449; DOI: 10.1158/1078-0432.CCR-12-3181
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Sirt7 Promotes Colorectal Cancer Tumorigenesis
  • Contact Guidance Controls T-cell Migration in PDAC
  • MET in Papillary RCC
Show more Human Cancer Biology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement